Tsugiya Murayama Selected Research

aluminoborate cement

1/2016	Synergistic effects by combination of ganciclovir and tricin on human cytomegalovirus replication in vitro.
10/2012	Anti-cytomegalovirus effects of tricin are dependent on CXCL11.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsugiya Murayama Research Topics

Disease

11	Infections 01/2022 - 01/2005
3	Virus Diseases (Viral Diseases) 01/2022 - 09/2011
1	Drug-Related Side Effects and Adverse Reactions 01/2016
1	Body Weight (Weight, Body) 08/2011
1	Astrocytoma (Pilocytic Astrocytoma) 06/2009
1	Glioma (Gliomas) 06/2009
1	Neuroblastoma 06/2009

Drug/Important Bio-Agent (IBA)

6	tricinIBA 05/2018 - 08/2011
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2009
2	Messenger RNA (mRNA)IBA 01/2016 - 10/2014
2	aluminoborate cementIBA 01/2016 - 10/2012
1	Antiviral Agents (Antivirals)IBA 01/2022
1	InterferonsIBA 01/2022
1	Phospholipid Transfer ProteinsIBA 01/2022
1	LigandsIBA 12/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	GelatinIBA 01/2016
1	progelatinaseIBA 01/2016
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2016
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2016
1	Matrix Metalloproteinases (MMPs)IBA 01/2016
1	ChemokinesIBA 10/2014
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2014
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2012
1	TankyrasesIBA 01/2012
1	Dinoprostone (PGE2)FDA Link 09/2011
1	NF-kappa B (NF-kB)IBA 06/2009
1	epoxomicinIBA 06/2009
1	benzyloxycarbonylleucyl-leucyl-leucine aldehydeIBA 06/2009
1	clasto-lactacystin beta-lactoneIBA 06/2009
1	Proteasome InhibitorsIBA 06/2009
1	Glycoproteins (Glycoprotein)IBA 01/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2005

Therapy/Procedure

1	Therapeutics 01/2016